WASHINGTON — In the high-stakes arena of surgical oncology, the question of "how much is enough" remains a perennial point of contention. For patients undergoing radical prostatectomy to treat intermediate- and high-risk prostate cancer, the scope of lymph node removal—whether limited or extended—has been a subject of significant debate. Now, new, long-term follow-up data from a pivotal Phase III randomized controlled trial, presented at the American Urological Association (AUA) annual meeting, suggests that for the vast majority of patients, less may indeed be more.
The study, which tracked patients for a median of 11 years, concludes that extended pelvic lymph node dissection (ePLND) offers no significant survival benefit over standard, limited lymphadenectomy (lPLND) in the general population of intermediate- and high-risk prostate cancer patients. While researchers identified a potential benefit for a specific subgroup of patients with high-grade disease, the broader findings have reignited a fierce debate among experts regarding surgical intensity, patient morbidity, and the changing landscape of diagnostic imaging.
The Main Facts: A Decade of Data
The trial, led by Dr. Jean Lestingi of the University of São Paulo, Brazil, sought to resolve a long-standing uncertainty in urologic surgery: Does removing a more comprehensive range of pelvic lymph nodes improve long-term outcomes compared to the more conservative, limited approach?
The trial randomized 300 patients with newly diagnosed, intermediate- to high-risk prostate cancer. Participants were split into two cohorts: one receiving ePLND (which removed a median of 17 lymph nodes) and one receiving lPLND (removing a median of three). The primary endpoint was biochemical recurrence-free survival (BRFS) at five years.
After 11 years of follow-up, the data proved sobering for proponents of more aggressive surgical intervention. There was no statistically significant difference in BRFS between the two groups (HR 0.92, 95% CI 0.66–1.29). Furthermore, secondary endpoints—including metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS)—remained indistinguishable between the two surgical approaches.
Chronology of the Research
The trajectory of this study reflects the evolving nature of clinical research in prostate cancer.
- Pre-2016: Enrollment for the study took place, concluding before the widespread clinical adoption of prostate-specific membrane antigen (PSMA) PET imaging, a technology that has since revolutionized the staging and detection of occult metastases.
- 2021: An earlier analysis of the trial was published, which first hinted at a potential benefit for patients with Grade Group (GG) 3–5 disease (high-grade tumors). This generated significant interest in the urological community, as it suggested that while the overall population saw no benefit, a subset of high-risk patients might see improved BRFS.
- 2024 (Present): The long-term follow-up data was presented at the AUA meeting. While the researchers reaffirmed the original findings regarding the lack of overall benefit, they expanded the scope of the potential benefit for the GG 3–5 subgroup, claiming an MFS advantage for those patients as well.
Supporting Data and the "High-Grade" Subgroup
The central point of discussion at the AUA meeting was the performance of the high-grade subgroup (GG 3–5). Dr. Lestingi noted that for these specific patients, the data shows a "significant and sustainable benefit" in biochemical recurrence-free survival.
"We now demonstrate the benefits in metastasis-free survival for these patients as well," Dr. Lestingi stated during the presentation. "We suggest that extended pelvic lymph node dissection could be considered a standard in these subgroups undergoing radical prostatectomy, and guideline recommendations should consider this updated data."
However, the statistical weight of this claim remains a subject of intense scrutiny. The subgroup analysis relies on a very small number of patients—31 in the ePLND group versus 38 in the lPLND group. The resulting hazard ratio for MFS, while statistically significant (HR 0.26, 95% CI 0.07–0.93), carries a wide confidence interval, leading many statisticians and clinicians to urge caution before declaring a new "standard of care."
Official Responses and Clinical Skepticism
While the study authors are advocating for a shift in surgical practice for high-grade cases, the reception from the broader surgical community has been notably skeptical. Dr. Alexander Kutikov, of the Fox Chase Cancer Center in Philadelphia, offered a sharp rebuttal to the suggestion that these results should change clinical practice.
"The pre-specified primary endpoint remains negative at long-term follow-up," Dr. Kutikov told MedPage Today. "Metastasis-free survival, cancer-specific survival, and overall survival are all flat. A positive p-value with longer follow-up in the same handful of patients does not convert it into Level 1 evidence."
Dr. Kutikov highlighted several critical limitations that he argues invalidate the case for ePLND:
- Improbable Assumptions: The trial was designed to detect a 15% absolute BRFS improvement, an effect size that many consider "implausibly large" for a surgical intervention of this nature.
- Conflicting Evidence: The results directly clash with a larger U.S.-based trial that also found no BRFS benefit, suggesting that any signal observed in MFS may be due to post-recurrence events rather than the surgical dissection itself.
- The "PSMA Era" Problem: Because the trial enrollment ended before PSMA PET scans became standard, the study’s diagnostic foundation is considered outdated. Today’s surgeons can often identify nodal involvement with much higher precision via imaging, potentially rendering extensive "blind" dissections unnecessary.
The Cost of Complexity: Morbidity and Quality of Life
Perhaps the most persuasive argument against the routine adoption of ePLND is the non-trivial increase in patient morbidity. Surgery is never "free" in terms of biological cost, and the data from this trial bears that out in stark detail.
Patients undergoing the extended procedure faced, on average:
- An additional 50 minutes of operating room time.
- 150 mL of additional blood loss.
- One additional day of hospitalization and one additional day requiring a surgical drain.
- A higher rate of symptomatic lymphocele (4% vs. 0%).
- A significant increase in Clavien-Dindo Grade I–II surgical complications (28% vs. 17.3%).
These figures are particularly concerning when juxtaposed with the lack of clear survival benefits. Comparisons were drawn to recent studies in bladder cancer, where extended lymphadenectomy similarly failed to show survival benefits but was associated with significantly higher 90-day mortality rates.
Implications: Where Do We Go From Here?
The implications of the Brazilian trial are two-fold. First, it serves as a powerful reminder that more aggressive surgical intervention does not automatically translate to better cancer outcomes. In the context of localized, intermediate- to high-risk prostate cancer, the biological reality of the disease—often characterized by systemic micrometastases—may be beyond the reach of regional lymph node removal.
Second, the study highlights the necessity of patient-centered surgical decision-making. As the field moves toward a more personalized approach, surgeons must weigh the potential for marginal, hypothesis-generating benefits in high-grade subgroups against the well-documented, immediate physical toll of extended surgery.
For the practicing urologist, the message is clear: while the allure of "doing more" in the operating room is strong, the current evidence base does not support a broad move toward extended lymphadenectomy. As Dr. Kutikov succinctly put it, "More pelvic dissection is not free—at all."
As clinical guidelines continue to evolve, the focus will likely shift away from the extent of surgical resection and toward better molecular profiling and more advanced preoperative imaging. The quest to improve survival in prostate cancer remains, but it is increasingly clear that the path forward lies in precision and diagnostic accuracy, rather than simply expanding the boundaries of the surgical field.
